Eagle takes sporadic flight on US Ryanodex nod
This article was originally published in Scrip
Executive Summary
The FDA granted Eagle Pharmaceuticals approval to market its orphan drug Ryanodex (dantrolene sodium) as a treatment for malignant hyperthermia (MH), an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible people.